D. E. Shaw & Co., Inc. Graphite Bio, Inc. Transaction History

D. E. Shaw & Co., Inc.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$2.18 - $2.77 $16,441 - $20,891	7,542 Added 18.91%	47,426 $117,000
Q2 2023 Aug 14, 2023	BUY	$2.47 - $3.38 $23,465 - $32,110	9,500 Added 31.27%	39,884 $103,000
Q1 2023 May 15, 2023	BUY	$1.85 - $3.21 $185 - $321	100 Added 0.33%	30,384 $74,000
Q3 2022 Nov 14, 2022	SELL	$2.82 - $4.24 $47,277 - $71,083	-16,765 Reduced 35.63%	30,284 $96,000
Q2 2022 Aug 15, 2022	BUY	$2.14 - $5.23 $100,684 - $246,066	47,049 New	47,049 $129,000
Q4 2021 Feb 14, 2022	SELL	$8.41 - $16.71 $449,699 - $893,517	-53,472 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$15.81 - $28.39 $845,392 - $1.52 Million	53,472 New	53,472 $876,000

637K

Ticker GRPH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,211,200
Description
Graphite Bio, Inc., a clinical-stage gene editing company, engages in developing therapies for serious and life-threatening diseases in the United States. It offers GPH101, a gene-edited autologous hematopoietic stem cell product candidate to directly correct the mutation that causes sickle cell disease and restore normal adult hemoglobin expres...

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.